ClinicalTrials.gg
RecruitingNCT01311323MILESTONEUpdated Jul 8, 2026

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

An interventional study of PCI and CABG in Multivessel Coronary Artery Disease and Acute Coronary Syndrome, sponsored by American Heart of Poland. Recruiting at 9 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by American Heart of Poland · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Acute Coronary Syndrome with a site in Poland — 12 open to participants now, 16 under way, 2 of them phase 3. Acute Coronary Syndrome · Poland.

Planned enrollment
35th of 49
1,000 · median 3,050
Started
2025
with 3 others
No phase
9 of 62
2 open now
Primary completion
2028-12
later than 13 of 15 live
Registered
29th of 62
by date

Among the 62 studies in Acute Coronary Syndrome with a site in Poland, this one is the 35th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 with no phase, reaches primary completion later than 13 of the 15 other live ones, and was the 29th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

12 of the 62 studies in Acute Coronary Syndrome with a site in Poland are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Acute Coronary Syndrome with a site in Poland, or all of them as a file.
02

Study summary

MILESTONE STUDY is dedicated to problems connected with patients with multivessel coronary artery disease and/or with left main narrowing who present symptoms of acute ischemia. For such kind of patients according to current ACC/AHA guidelines CABG (surgical revascularization) is recommended as a treatment method. In comparison with CABG, recent studies have shown that PCI (percutaneous coronary intervention) is associated with a lower rate of periprocedural adverse events and similar long term event-free survival in patients with left main disease. Our latest non randomized registry and randomized LEMANS study, comparing LMCA (left main coronary artery) stenting with CABG confirmed above findings. LEMANS ACS (acute coronary syndrome) retrospective registry of patients with UPLMCA (unprotected LMCA) disease and non ST elevation ACS showed lower 30 day and trend toward lower one year mortality after PCI when compared with CABG. It should be stressed, that acute ischemia substantially increase the risk of CABG. In fact, there are limited data on the outcome of ULMCA stenting or CABG in patients with acute coronary syndromes (ACS).

Similarly, all randomized studies comparing PCI vs CABG in multivessel disease included mainly patients with stable angina, small cohort of patients with unstable angina and they excluded patients with non ST elevation Myocardial infarction.

In the SYNTAX study -largest PCI vs CABG trial, randomized patients were patients with low perioperative risk (logistic EUROSCORE \<5) and ACS patients routinely excluded. High perioperative risk patients were included only in PCI registry.

Read the detailed description

Within last decade, aging of the population and coexistence of multiple comorbidities influenced a risk of patients presenting with acute coronary syndrome (ACS). Furthermore, a steady decline in ST elevation ACS incidence and increase in non-ST elevation acute coronary syndrome (NSTE-ACS) has been observed, associated with poorer long term prognosis. This is related to the complexity of coronary artery disease in patients with NSTE-ACS, as nearly half of them have multivessel disease (MVD). The optimal revascularization strategy in this group of patients remains unknown. Due to clinical presentation in most of cases early or delayed invasive strategy is preferred by both American and European guidelines, however the method of revascularization is not specified. Due to high surgical risk presentation, immediate stenting of the culprit lesion and delayed complete percutaneous revascularization is becoming a common practice. On the other hand, basing on the anatomical criteria coronary artery bypass grafting (CABG) should be the standard of care . Very few reports addressed so far the problem of optimal revascularization strategy in patients presenting with MVD and NSTE-ACS. A hypothesis of a positive outcome can be derived from some previous studies comparing PCI and CABG in which most of patients enrolled presented with NSTE-ACS, including our experience.

Aim and hypothesis:

Hence, the purpose of this study will be to compare contemporary coronary angioplasty with coronary artery bypass grafting in a prospective, clinical, multicenter, randomized trial. The hypothesis of this study is the non-inferiority of PCI compared to CABG in terms of the primary composite endpoint (death, myocardial infarction, stroke).

Method:

Patients with multivessel coronary artery disease, left main and acute coronary syndrome without ST segment elevation, qualified for early invasive treatment, with a Syntax Score below 33, and in whom the invasive cardiologist and cardiac surgeon will recognize both PCI and CABG as possible to achieve complete revascularization will be enrolled to the study. In the case of centers without the Cardiac Surgery Department, "Heart Team" consultations will take place via videoconference, and records of coronarography and echocardiography will be shared via the PACS (ang. Picture Archiving and Communication System system). The main exclusion criteria will be the qualification for conservative treatment, surgery other than CABG due to structural heart defect, ST segment elevation myocardial infarction, stable coronary artery disease, immediate need for PCI. After fulfilling the inclusion criteria and lack of exclusion criteria, the patient will be randomized in a 1: 1 ratio to either PCI or CABG. The PCI procedure will be performed after assessing the hemodynamic significance of all lesions with vFFR, FFR or iFR or using the latest generation drug eluting stents, and the implantation will be optimized based on intravascular imaging. CABG procedures will be performed based on the experience of the respective center, including the OPCAB technique, and the internal mammary artery will be used in each case. The primary endpoint of the study will be all cause death, myocardial infarction, and stroke in one-year follow-up. To prove the assumed hypothesis of the study, with the test power of 80% alpha error 5% and the percentage of lost to follow-up at the level of 5%, the study should include 500 patients in each group. Secondary endpoints will be ischemia driven revascularization, left ventricular ejection fraction, major and minor bleeding incidence, new onset of atrial fibrillation, de novo heart failure, unscheduled re-hospitalization, quality of life, and cost effectiveness. After the hospitalization, patients will be subjected to strict secondary prevention principles, including cardiac and cardiac surgery rehabilitation, and will undergo four specialistic follow-up visits with cardiac echo and stress tests at selected time points.

Anticipated outcomes:

In the case of positive results of the study, the efficacy and safety of PCI in the studied group of patients will be confirmed. This will contribute to the creation of a new guidelines in a given area, translating into faster and easier access to rapid invasive treatment. It will also facilitate the decision-making process in centers without cardiac surgery.

03

Conditions studied

  • Multivessel Coronary Artery Disease
  • Acute Coronary Syndrome

Keywords

  • Multivessel Coronary Artery Disease
  • Left Main Narrowing
  • Percutaneous Coronary Intervention
  • Coronary Artery Bypass Grafting
  • Drug-Eluting Stent
  • Fractional Flow Reserve
  • Instant wave-free ratio
  • virtual Fractional Flow Reserve
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet ALL of the inclusion criteria to be considered for the trial. If ANY of the exclusion criteria are met, the subject is excluded from the trial and cannot be randomized.

  • Age over 18 years,
  • Written patient consent,
  • Acute Coronary Syndrome without ST-segment elevation of high, intermediate and low risk, including NSTEMI and unstable angina requiring urgent (within 72 hours) invasive strategy,
  • Qualification for invasive treatment,
  • Multivessel coronary disease, defined as angiographic narrowing >50%DS on investigator's visual assessment in at least two major coronary artery territories (RCA, LAD, LCX), including involvement of the proximal segment of the left anterior descending artery or three-vessel disease with a Syntax Score \< 33. Intermediate lesions (40-70%) will need to be assessed with either FFR, iFR, or VFFR). Patient may have left main coronary artery disease, defined as narrowing >50%DS (but this is not obligatory). For borderline changes, IVUS (MLA \<6 mm2 or iFR=\<0,90 or FFR=\<0,80, with an anatomic Syntax Score \<33 will be decisive,
  • Feasibility of complete revascularization on both the CABG and PCI sides,
  • Consent within the Heart Team for both CABG by the cardiothoracic surgeon and PCI by the interventional cardiologist.

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years,
  • ST-segment elevation myocardial infarction (STEMI) or new left bundle branch block (LBBB),
  • Stable coronary syndrome,
  • Single- or two-vessel coronary disease without involvement of the proximal LAD, defined as narrowing above 50%DS,
  • Qualification for conservative treatment,
  • Anticipated surgery other than CABG due to severe valvular defect or other structural defect, particularly moderate or severe mitral regurgitation,
  • Need for immediate coronary angioplasty treatment,
  • Syntax Score equal or above 33 (>=33),
  • to short-term and long-term antiplatelet therapy,
  • Acute heart failure in class IV (cardiogenic shock),
  • Previous CABG procedure,
  • Previous PCI procedure within the last 6 months,
  • Ischemic or hemorrhagic stroke within 6 months prior to inclusion,
  • End-stage chronic kidney disease on dialysis,
  • Pregnancy or intention to become pregnant (women of child bearing age must have a recent negative pregnancy test prior to randomization),
  • Non cardiac co-morbidities with less than 3 years,
  • Participation in other clinical trial that have not reached their primary endpoint.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    PCI with DES implantation

    Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents

    Procedure: PCI

  • Active comparator
    CABG

    Coronary Artery Bypass Grafting.On-pump or Off-pump CABG

    Procedure: CABG

Interventions

  • ProcedurePCI

    Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging

    Also known as: •Percutaneous coronary intervention, •Multivessel coronary disease, •Left main narrowing

  • ProcedureCABG

    Coronary Artery Bypass Graft

    Also known as: Multivessel coronary artery disease, Coronary artery bypass graft, Left Main narrowing

06

What researchers measure

Primary outcomes

  1. MACCE - Major Adverse Cardiac and Cerebral Events

    The primary endpoint is a composite of all cause death, spontaneous myocardial infarction, hospitalization due to heart failure or heart failure decompensation and stroke occurring within 12 months after PCI or CABG. The hypothesis test is designed to show non-inferiority of PCI to CABG for the primary endpoint

    Time frame: One year after revascularization procedure

Secondary outcomes

  1. SAE - Serious Adverse Events

    ischemia driven revascularization, left ventricular ejection fraction, major and minor bleeding incidence, new onset of atrial fibrillation, de novo heart failure, unscheduled re-hospitalization

    Time frame: peri-hospital period, one month and one year and two years after revascularization procedure

  2. Procedural and post procedural complication

    Procedural and post procedural complication: length of hospital stay and frequency of prolonged hospitalization ; return to work; readmissions and cause of readmissions; angina and functional status; medications.

    Time frame: peri-hospital period, one month and one year after revascularization procedure

  3. Overall costs of treatment strategies.

    Hospital costs and long-term cost-effectiveness.

    Time frame: one year ofter revascularization procedure

  4. Occurence of stent thrombosis or graft occlusion

    Stent trombosis will be defined in accordance with ARC definition.

    Time frame: peri-hospital period, one month and one year after revascularization procedure

  5. Hemorrhagic complications.

    Hemorrhagic complications will be clasified according to TIMI scale.

    Time frame: peri-hospital period, one month and one year after revascularization procedure

  6. Frequency and impact of complete revascularization

    Complete revascularization will be defined on an anatomic basis and by revascularization of all significant ischemic areas.

    Time frame: one year after revascularization procedure

  7. LVEF

    Left Ventricle Ejection Fraction

    Time frame: 6 and 12 months

07

Study locations

9 of 9 sites recruiting
  • Małopolska Cardiovascular Center, Polish-American Heart Clinic in Chrzanów
    Chrzanów, Malopolska 32-500, Poland
    Recruiting
  • Polish-American Heart Clinics Center for Cardiology and Cardiac Surgery Outpatient Specialist Care in Bielsko-Biała
    Bielsko-Biala, Silesian Voivodeship 43-316, Poland
    Recruiting
    • Piotr Buszman, MD, PhD, Prof · ContactPiotr.Buszman@ahop.pl · (+48) 33 472 63 20
    • Monika Filary · Contactmonika.filary@ahop.pl · 33 472 6334
    • Piotr Buszman, MD,PhD, Prof · Principal investigator
    • Krzysztof Milewski, MD,PhD, Prof · Sub investigator
    • Krzysztof Sanetra, MD,PhD · Sub investigator
    • Witold Gerber, MD,PhD · Sub investigator
  • Polish-American Heart Clinics III Department of Invasive Cardiology, Angiology and Electrocardiology
    Dąbrowa Górnicza, Silesian Voivodeship 41-300, Poland
    Recruiting
    • Łukasz Konarski, MD · Contactlukasz.konarski@ahop.pl · (+48) 32 764 30 30
    • Łukasz Konarski, MD · Principal investigator
  • Polish-American Heart Clinics, 1st Department of Cardiology and Angiology in Ustroń
    Ustroń, Silesian Voivodeship 43-450, Poland
    Recruiting
  • Upper Silesian Medical Center in Katowice
    Katowice, Poland
    Recruiting
  • Polish-American Heart Clinics Cardiovascular Center in Kędzierzyn-Koźle
    Kędzierzyn-Koźle, Poland
    Recruiting
  • University Clinical Hospital in Opole
    Opole, Poland
    Recruiting
  • Polish-American Heart Clinics X Department of Invasive Cardiology, Electrophysiology and Electrostimulation in Tychy
    Tychy, 43-100, Poland
    Recruiting
  • National Medical Institute of the Ministry of the Interior and Administration
    Warsaw, Poland
    Recruiting
08

References and documents

Publications

  • Park DW, Kim YH, Yun SC, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Kim JJ, Choo SJ, Chung CH, Lee JW, Park SW, Park SJ. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry. J Am Coll Cardiol. 2010 Oct 19;56(17):1366-75. doi: 10.1016/j.jacc.2010.03.097. PubMed 20946993 ↗
  • Park DW, Seung KB, Kim YH, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Gwon HC, Jeong MH, Jang YS, Kim HS, Kim PJ, Seong IW, Park HS, Ahn T, Chae IH, Tahk SJ, Chung WS, Park SJ. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol. 2010 Jul 6;56(2):117-24. doi: 10.1016/j.jacc.2010.04.004. Epub 2010 May 6. PubMed 20451344 ↗
  • Buszman PE, Buszman PP, Kiesz RS, Bochenek A, Trela B, Konkolewska M, Wallace-Bradley D, Wilczynski M, Banasiewicz-Szkrobka I, Peszek-Przybyla E, Krol M, Kondys M, Milewski K, Wiernek S, Debinski M, Zurakowski A, Martin JL, Tendera M. Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry. J Am Coll Cardiol. 2009 Oct 13;54(16):1500-11. doi: 10.1016/j.jacc.2009.07.007. Epub 2009 Aug 21. PubMed 19699048 ↗
  • Buszman PP, Bochenek A, Konkolewska M, Trela B, Kiesz RS, Wilczynski M, Cisowski M, Krejca M, Banasiewicz-Szkrobka I, Krol M, Kondys M, Wiernek S, Orlik B, Martin JL, Tendera M, Buszman PE. Early and long-term outcomes after surgical and percutaneous myocardial revascularization in patients with non-ST-elevation acute coronary syndromes and unprotected left main disease. J Invasive Cardiol. 2009 Nov;21(11):564-9. PubMed 19901409 ↗
  • Buszman PE, Kiesz SR, Bochenek A, Peszek-Przybyla E, Szkrobka I, Debinski M, Bialkowska B, Dudek D, Gruszka A, Zurakowski A, Milewski K, Wilczynski M, Rzeszutko L, Buszman P, Szymszal J, Martin JL, Tendera M. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008 Feb 5;51(5):538-45. doi: 10.1016/j.jacc.2007.09.054. PubMed 18237682 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 40 months is above that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2011
First posted
Mar 9, 2011
StartActual
Aug 25, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Nov 2030
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01311323
Lead sponsor
American Heart of Poland
Collaborators
Andrzej Frycz Modrzewski Krakow University
Responsible party
Piotr P Buszman, MD (M.D., PhD, Professor, American Heart of Poland) — Principal investigator
First posted
Mar 9, 2011
Start date
Aug 25, 2025
Primary completion
Dec 2028 (estimated)
Completion
Nov 2030 (estimated)
Last update
Jul 8, 2026

Study contacts

Natalia Pydyn, PhD
Contact
natalia.pydyn@ahop.pl
+48 667 132 233
Piotr P Buszman, MD,PhD, Prof
principal investigator · American Heart of Poland
Krzysztof Sanetra, MD, PhD
principal investigator · American Heart of Poland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion